Hodgkin’s Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio – Fortaleza, Brazil.

Abstract

SUMMARY The Autologous HSCT is an important alternative for refractory or recurrent HL patients in terms of survival and improved quality of life. This study analyzes the results of autologous BMT performed in HL patients in the Transplant Unit of the HUWC/ HEMOCE (Fortaleza - CE, Brazil). Fifty-two transplanted patients were studied from January 2009 to October 2015, among them, 30 men and 22 women, mean age of 28.2 years. All of them received GCS-F during the mobilization, in some cases associated with Vinorelbine or Plerixafor, with CD34 collection averaging 4.8 CD34/kg. The conditioning was performed with BEAC, NEAM or BEAM and the grafting with an average of 10 days. The evaluation on D + 100 showed: CR - 42 (82.7%), PR - 08 (13.5%) and 02 (3.8%) deaths, three and six days after cell infusion. After the D+100, 08 patients in CR showed HL recurrence from 06 to 36 months; 03 died and 05 are being treated with brentuximab; among the 08 patients in PR, 01 died due to HL activity, 04 months after BMT and 07 patients are undergoing treatment. The final evaluation of HL transplant patients showed an OS of 88.5% and a DFS of 61.5% in 6 years, with OS of the chemosensitive patients of 81% and of the chemoresistant ones, of 72.6%. It is possible to conclude that the Autologous HSCT has shown to be an excellent rescue therapy regarding tolerance, as well as the overall survival.

Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors

“…Given the early incidence and improved survival rates of HL, 21 as well as the psychosocial burden and impact of this disease on the patients’ daily life, 22 establishing a framework of comparison for the assessment of HRQoL in this clinical population is essential. This study provides reference values for the EORTC QLQ‐C30 for patients with HL and survivors.…”

“…This study was not without limitations. First, the high incidence of HL in young adults 21 and the very nature of survivors’ samples induced an age imbalance between the two clinical groups being compared. Second, the patient group was exclusively composed by patients diagnosed with an advanced stage of HL, which might not be representative of patients with early‐stage HL.…”

Linfoma de Hodgkin: Análise de desfechos em óbito no Brasil, na região Norte e no Amapá em uma década

“…Pacientes submetidos ao tratamento, a depender do estágio ao diagnóstico e fatores de risco envolvidos, podem entrar em remissão da doença em cinco anos. Apesar de protocolos eficazes e com bons prognósticos, até alcance de cura em alguns pacientes, outros são refratários ou apresentam recorrência do linfoma, cerca de 10% e 20 a 25%, respectivamente (Duarte et al, 2016;Küppers, Engert, & Hansmann, 2012).…”

The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience

“…Despite these advancements, approximately 10% of HL patients remain refractory to these treatments in whom auto-HSCT remains one of the most important alternative treatment modalities. [24] Plerixafor is an additional option for use in auto-HSCT. G-CSF with plerixafor augments the mobilization of CD34 + cells, particularly in patients who are considered poor mobilizers.…”